By Adria Calatayud

Sanofi said it would end a clinical-development program for its tusamitamab ravtansine drug candidate after a late-stage trial in previously treated patients with nonsmall cell lung cancer didn't meet its primary goal.

The French pharmaceutical company said the decision came after an independent data monitoring committee found that tusamitamab ravtansine as a monotherapy didn't meet its primary goal of progression-free survival compared to docetaxel. The trial had dual primary goals of progression-free survival and overall survival.

While overall survival improved, the decision on the trial was based on a lack of improvement on progression-free survival, Sanofi said Thursday.

Tusamitamab ravtansine had a similar safety profile as previously presented, the company said.

Sanofi said it will continue exploring the potential of tusamitamab-based antibody drug conjugates and research on the potential of certain molecules as biomarkers in several types of cancer.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

December 21, 2023 02:10 ET (07:10 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Sanofi.
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Sanofi.